The comparison of the ex-vivo biodistribution between the two 45Ti-labeled compounds showed that tumor uptake rose from 0.18% ID/g for [45Ti]salan-Ti-dipic to 1.1% ID/g for [45Ti]salan-Ti-CA-PSMA (Figure 4, right). The gene discussed is FOLH1; the disease is neoplasm.